While KAL did not have a notable day on the price appreciation side, the volume in the stock may be setting us up for better days ahead.

In addition to the strong volume day, the company was out with more good news after the market closed today. Atiprimod, the company’s developing drug for the virtually untreatable Mulitple Myeloma, has been chosen for oral presentation at the  American Society of Hematology next month in Atlanta, GA.

The ASH is the most prestigious body of scientists and doctors who deal with blood disorders. KAL will be presenting findings from an animal study and anti-tumor activity in elegant models of multiple myeloma developed by researchers at Dana-Farber, as well as evaluation of genes that are affected in multiple myeloma cells exposed to the drug.

This is a very positive development for both Antiprimod and KAL. Early clinical data is making the blood disorder community take notice. To read the entire text of the press release, click here.

Yesterday’s edition on KAL’s patent for a new colon cancer treatment contained an inaccuracy. The edition stated KAL had received a patent approval. In fact, what they have received is a “Notice of Allowance” of a patent. This means the patent office has decided to allow the patent, formal issuance to come soon. I am informed it is almost always a ”fait accompli”.

Here’s a daily chart of KAL throughout 2005. Note that today was the third highest volume day of 2005.  Past high volume days have preceeded a nice move up in the stock.

It’s all about the volume. Since September the volume has been increasing. If the volume can just stay up there, eventually the stock will break out. Hard to say when, but the way the company is going a better market should deliver a much higher price.